Drugs / AVIZAKIMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03036865 | Jan 2017 → Apr 2018 | — | Boston Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03371251 | Jan 2018 → Nov 2020 | systemic lupus erythematosus | Boston Pharmaceuticals | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVIZAKIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594532 ↗ |
| Known as | BOS161721 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03036865 ↗ |
| Known as | Medi 7169 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594532 ↗ |
| Action | Inhibit | “inhibits interleukin-21 (IL-21) bioactivity” PMID 31664766 ↗ Nov 2019 |
| Modality | Monoclonal antibody | “a humanized immunoglobulin G1 triple mutation (M252Y/S254T/T256E) monoclonal antibody” PMID 31664766 ↗ Nov 2019 |
| Route | Intravenous | “single ascending intravenous and subcutaneous doses of BOS161721” PMID 31664766 ↗ Nov 2019 |
| Route | Subcutaneous | “single ascending intravenous and subcutaneous doses of BOS161721” PMID 31664766 ↗ Nov 2019 |
| Target | IL21 | “inhibits interleukin-21 (IL-21) bioactivity” PMID 31664766 ↗ Nov 2019 |